Paper: A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Tagraxofusp in Relapsed/Refractory Myelofibrosis after JAK Inhibitor Therapy (from #ASH21)

Read the full article here

Related Articles